Answers are grounded in this paper and cite their sources.
Pooled safety analysis evaluates zanubrutinib's appropriateness for Asian patients with B-cell malignancies, suggesting favorable outcomes.
Zanubrutinib was well tolerated in Asian patients with B-cell malignancies. The safety profile in this population was consistent with that in previous global study populations. These findings suggest that long-term zanubrutinib treatment is an appropriate option for Asian patients with B-cell malignancies.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: